AF
AKRO

Allworth Financial’s Akero Therapeutics AKRO Stock Holding History

Allworth Financial’s Portfolio AKRO Stock Details AKRO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-90
Closed -$4.27K – 5011
2025
Q3 		$4.27K Sell
90
-105
-54% -$5.08K ﹤0.01% 3641
2025
Q2 		$10.4K Sell
195
-37
-16% -$1.68K ﹤0.01% 2874
2025
Q1 		$9.51K Hold
232
– – ﹤0.01% 2446
2024
Q4 		$5.8K Hold
232
– – ﹤0.01% 2690
2024
Q3 		$6.66K Hold
232
– – ﹤0.01% 2443
2024
Q2 		$6.21K Hold
232
– – ﹤0.01% 2414
2024
Q1 		$5.86K Sell
232
-9
-4% -$216 ﹤0.01% 2343
2023
Q4 		$5.63K Sell
241
-495
-67% -$9.76K ﹤0.01% 2227
2023
Q3 		$37.2K Hold
736
– – ﹤0.01% 1227
2023
Q2 		$34.4K Hold
736
– – ﹤0.01% 1260
2023
Q1 		$28.2K Hold
736
– – ﹤0.01% 1285
2022
Q4 		$40.3K Hold
736
– – ﹤0.01% 1094
2022
Q3 		$25K Buy
736
+536
+268% +$8.2K ﹤0.01% 1201
2022
Q2 		$2K Hold
200
– – ﹤0.01% 1976
2022
Q1 		$3K Buy
+200
New +$3.5K ﹤0.01% 1694

Other funds holding AKRO

DekaBank Deutsche Girozentrale
DekaBank Deutsche Girozentrale Frankfurt, Germany $59.2B AUM 26.02% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Allworth Financial's AKRO Position: Q4 2025 in Review

Allworth Financial sold out of Akero Therapeutics (AKRO) in Q4 2025, closing a stake of 90 shares — an estimated $4.27K sold.

Allworth Financial first reported a position in AKRO in Q1 2022 and held it in 15 quarters. The position peaked at $40.3K in Q4 2022. 2 funds tracked by Wall St. Rank hold AKRO as of Q4 2025.

  • Allworth Financial reported no remaining Akero Therapeutics position as of Q4 2025 after selling out during the quarter.
  • Allworth Financial sold 90 Akero Therapeutics shares in Q4 2025, an estimated $4.27K.
  • Allworth Financial first reported a position in Akero Therapeutics in Q1 2022 and held it in 15 quarters.
  • Allworth Financial's Akero Therapeutics position peaked at $40.3K in Q4 2022.
  • 2 funds tracked by Wall St. Rank held Akero Therapeutics as of Q4 2025.

Based on Allworth Financial's 13F filing for Q4 2025, filed 5 Feb 2026.